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Abstract 
Prognostic factors and long-term treat-
ment response of interferon β-1a s.c tiw has
not been studied in a real-life clinical cohort
in Finland. The aim of the paper was to
evaluate long-term treatment response,
prognostic clinical factors and adherence
among interferon β-1a s.c tiw treated
patients in Finland. A retrospective review
of medical records was performed.
Confirmed relapsing multiple sclerosis
patients treated with interferon β-1a s.c tiw
22µg or 44µg as their first treatment, from
1996 to 2010 in Western Finland, were
included. Longitudinal generalized linear
regression models were applied to assess
risk of disability progression, using
Expanded Disability Status Scale (EDSS),
during the treatment period. Odd’s ratios
with 95% confidence intervals (95% CI)
were calculated for risk factors: gender, age
at diagnosis, treatment delay, dose, baseline
EDSS and EDSS change in one year.
Kaplan-Meier was applied to study median
time to discontinuation. Mean duration of
treatment in 293 cases was 2.9 years (min
0.04, max 13.5). EDSS increase vs. no
increase in one-year carried a significant
risk for long-term disability progression
(1.20, 1.08-1.33). Older age, defined by a
10-year increase in age at diagnosis (1.43,
1.07 -1.91) and one-year delay to treatment
start showed an increased risk for disability
progression (1.05, 0.99-1.11), but gender
(0.66, 0.38-1.15) or initial dose (1.00, 0.45-
2.25) showed no risk. Treatment was
stopped in 37% due to disease activation at
median of 1.7 years, and in 25% due to side
effects at 9.3 months. Our results show that
young age, a short delay to treatment start
and slower disability progression were
identified as factors for better outcome
among cases with interferon β-1a s.c tiw as
their first disease modifying treatment.
Introduction
The increasing number of approved
treatments for relapsing multiple sclerosis
(MS) shows varying levels of efficacy and
safety.1 To date, there are more than a dozen
approved treatments for MS, including the
injectable therapies, which are generally
considered as a safe treatment option.2 The
optimal treatment success is still challeng-
ing and there is not yet consensus on the
best treatment strategy or treatment target in
MS.3 Prognostic factors for long-term clini-
cal outcomes are needed to help in treat-
ment management.4
The aim of the present study is to assess
the long-term clinical outcome and treat-
ment adherence among patients treated with
interferon β-1a s.c. tiw in Finland.
Interferon β-1a s.c. tiw is 100% reimbursed
by Finnish Social Security Insurance (SII)
from 1996 in active relapsing MS and used
with doses of 22 and 44 µg tiw. Patients
who were initially treated with interferon β-
1a s.c. tiw during the follow-up period from
1996 to 2010 are included in the study. 
Materials and Methods
The National Institute for Health and
Welfare and the local ethical standards com-
mittee approved the retrospective examina-
tion of identified patient records. Cases in
this retrospective long-term real-life study
are confirmed relapsing MS patients diag-
nosed by using Poser and McDonald crite-
ria during 1981-2010 at the neurological
hospital clinics, which belong to Tampere
University Central Hospital districts in
Western Finland.5,6 Patients who initiated
interferon β-1a s.c tiw 22µg or 44µg during
1996-2010 as their first disease modifying
treatment (DMT) were included in the
study. The follow-up period of the study
was from 1996 to 2010.
Data was collected for gender, age at
diagnosis, time from disease onset to treat-
ment initiation, time from diagnosis to treat-
ment initiation, treatment duration from
treatment start to cessation. Disability pro-
gression was estimated by using longitudi-
nal Expanded Disability Status Scale
(EDSS) measures.7 In the longitudinal
analysis the EDSS value was always com-
pared to the previous reported EDSS value.
Therefore, the change is dependent on the
previous value and not on the baseline
value. Initial EDSS value at treatment start
(baseline EDSS), yearly EDSS change dur-
ing the treatment, and causes for discontin-
uation were collected from hospital patient
charts by authors AM and MLS.
Treatment reimbursement requirements
for DMTs in MS in Finnish SII are active
disease and description of patients’ disabili-
ty status. This and patients’ status informa-
tion were available from hospital patient
records. Disability was assessed by using
EDSS in majority of the patient records and
in case it was described authors (AM, MLS)
applied EDSS scale retrospectively based
on recorded status information. 
Generalized linear regression models
were used to assess Odd’s ratios (OR) with
95% confidence intervals (95% CI) for
covariates: gender, age at diagnosis, time
from diagnosis to treatment start, dose of
interferon β-1a s.c tiw, baseline EDSS and
EDSS change in one year. For statistical
analyses baseline EDSS values were cate-
gorized into three groups: EDSS 0-1, EDSS
1.5-2.5 and EDSS 3.0 or greater.
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Kaplan-Meier (K-M) curve with Log
Rank test was used to study the difference
in the times on treatment in groups catego-
rized based on the cause of discontinuation.
Causes of discontinuation were classified
into three groups as follows: 1. Side effects
included flu like reactions, any medication
related laboratory value change or injection
related skin problems, 2. MS activation, in
case patient experienced a new relapse or
disability progression was observed, 3.
Other causes: Neutralizing antibodies, at six
months (180 days or more) after medication
start, lack of adherence or discontinuation
due to economical causes, pregnancy (gra-
vidity or a pregnancy plan). 
Results
A total of 293 patients, female/male
ratio 207/86, started interferon β-1a. s.c tiw
as first treatment during the follow-up. At
treatment start (baseline) mean age was
36.4 years. The time from disease onset to
treatment initiation was 6.3 years and the
time from diagnosis to treatment initiation
was 2.8 years. Mean baseline EDSS was
1.7. (Table 1). Altogether 290 EDSS values
from a total of 179 patients were recorded
during the follow-up. Distribution of cases
in baseline EDSS categories shows majority
in group 0-1.0: 55.6% (n=163), in 1.5-2.5
17% (n=50) and in >3.0 27.3% (n=80). No
gender difference existed in baseline EDSS
categories (Chi sq 0.88). Compliance to
regular treatment visits was good and yearly
information for disability was available in
all included cases. Five cases of death were
recorded during the follow-up period and in
three cases treatment was used up to
patients’ death; deaths were not related to
interferon β-1a s.c tiw.
Mean duration of the first treatment
(doses 22 µg or 44 µg) was 2.9 years (SD
2.9, min 0.04, max 13.5 years), no differ-
ence was observed between baseline EDSS
groups (F value 0.98, P<0.001). Disease
activation in 37.3% (n=77) and side effects
25.2% (n=52) were the main causes of dis-
continuation in the majority of the 209
cases, excluding deaths (n=3). Side effects
were injection related (n=12), other side
effects (n=37) and flu like symptoms (n=3).
Other causes were neutralizing antibodies
in 15.4 % (n=31), pregnancy in 9.7% %
(n=20), no disease activity 3.4% (n=7),
other causes 9.2% (n=19). Total of 84 cases
were on treatment at the end of follow-up in
2010. Mean time on treatment among these
cases was 3.98 years (min 0.04, max 13.5
years). Figure 1 shows K-M curve for the
time in years from interferon β-1a. s.c tiw
start to discontinuation by discontinuation
cause. Median time to discontinuation in
case of any side effects (n =52) was 9.3
months (280 days), activation of disease
(n=77) 1.7 year (20.5 months; 616 days)
and other causes (n= 77) 2.3 years (28.1
months; 843 days). EDSS values in yearly
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Table 1. Characteristics of the study population.
                                                                                     No.                                        %
Total                                                                                                      293                                                   100
Men                                                                                                        86                                                   29.4
Women                                                                                                 207                                                  70.6
Interferon β-1a s.c tiw 22µg                                                            252                                                  86.0
Interferon β-1a s.c tiw 44µg                                                             41                                                   14.0
                                                                            Mean, Median                             SD
Age at diagnosis, years                                                                33.6, 32.0                                              9.5
Age at treatment initiation, years                                             36.4, 36.0                                             10.1
Time to treatment from onset, years                                        6.3, 4.0                                                6.8
Time from diagnosis to treatment, years                                 2.8, 1.0                                                4.6
EDSS at treatment initiation                                                        1.7, 1.0                                                1.6
Duration of treatment period, years                                          2.9, 1.9                                                2.9
Figure 1. Time from interferon β-1a. s.c tiw start to discontinuation by cause. K-M curve.
Time to discontinuation (years) of treatment (n=206) in groups: Side effects (n=52), MS
activation (n=77) and other causes (n=77).
Figure 2. Number of MS cases on β-1a. s.c tiw, observed absolute, mean and median
EDSS values and SD in yearly intervals from baseline at start during follow-up period
from 1996 to 2010. 
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intervals by treatment duration are given in
Figure 2. The mean EDSS points at mild
disability (3.0 or less) during the first 3
years of treatment. 
Results in the longitudinal analysis are
shown in Figure 3. A statistically increased
risk for disease progression related to one-
point one-year increase in EDSS (1.20,
1.08-1.33). Ten-year increase in age at diag-
nosis increased the risk for progression sig-
nificantly (1.43, 1.07 -1.91). High baseline
EDSS value (>3) as compared to a low
baseline EDSS (0-1.0) value showed a sta-
tistically significant lower risk for disease
progression assessed by EDSS increase
(0.25, 0.10-0.63). No statistically signifi-
cant risk was shown for gender (0.66, 0.38-
1.15) or initial dose of interferon β-1a s.c
tiw (1.00, 0.45-2.25). Yearly delay from
diagnosis to treatment start was close to sta-
tistical significance (1.05, 0.99-1.11)
(Figure 3 and Supplementary Table 1). 
Discussion and Conclusions
We studied clinical outcomes in relaps-
ing MS cases with interferon β-1a s.c tiw as
the first treatment during the 14-year fol-
low-up from 1996 to 2010 in neurological
hospital clinics in Western Finland. A total
of 293 confirmed relapsing-remitting MS
cases fulfilling the Finnish SII reimburse-
ment criteria were included. We observed a
good compliance to treatment, based on the
accurate information in patient records at
regular yearly visits. Disability status by
EDSS was assessed at yearly visits by the
treating neurologist. At interferon β-1a s.c.
tiw start the mean baseline EDSS was 1.7,
mean age 36.4 years and time to treatment
initiation 2.8 years from diagnosis. The
observed long delay reflects the variable
diagnostic year from 1981 to 2010 in this
cohort, where in some cases diagnosis was
assessed years before the availability of
interferon β-1a s.c. tiw in 1996.
EDSS scale is considered a sensitive tool
to assess changes in disease progression.8
However, some studies have shown that the
rates of change vary depending on the initial
value, and several reports point at higher
annual rates of change (disability progres-
sion) at low EDSS baseline but little change
from EDSS score of 6 onwards.9,10 These
observations are important when disability
progression is determined by EDSS during
the treatment. In our data a low EDSS 0-1.0
carried a greater progression risk as com-
pared to EDSS >3.0, evaluated by increase in
EDSS score in the longitudinal study. The
prognostic benefit, however, related strongly
to a younger age, pointing at the significance
of early treatment initiation, which was sup-
ported by the negative impact for increasing
the time to treatment initiation. Considering
the limitations regarding the use of EDSS
scale, the risk for disease progression, how-
ever, related to one-point increase in yearly
EDSS, which corroborates results in other
interferon-β studies.11,12 Here no risk related
to gender, supporting the results that there is
no indication of different effects of interfer-
on-β in men or women.13 The result that the
initial dose of interferon showed no effect on
the risk, is likely due to the differences in the
number of patients in the groups, and overall
low number of patients especially in the 44
µg group.
The mean duration of the first treatment
with interferon β-1a s.c. tiw was almost
three years. The treatment periods thus
remained relatively short for deciphering the
long-term treatment responses. Disability
progression reached a mean EDSS 5.0 from
baseline for cases who had stayed on treat-
ment up to 10 years or more, reflecting a
moderate disability at this point. A total of
84 cases were on interferon β-1a s.c. tiw
treatment at the end of follow-up in 2010.
During the 14-year follow-up the treatment
was stopped in 70%. Disease activation at
mean of 1.7 years (37.3%) and side effects at
mean of 9.3 months (25.2%) were the main
causes. Percentage for stopping interferon-β
treatment in another study was only 18%
during 6-year- follow up (mean 3.5±2.1
years), where the main reason for treatment
discontinuation was lack of efficacy (54%)
and 21% of patients stopped therapy
because of pregnancy and only 17% because
of AE.14 Differences as compared to our
results may be explained by a longer follow-
up in our cohort. Furthermore, disease activ-
ity and progression in interferon β-1a s.c tiw
treated cases today may be detected early
after baseline by using MRI.15 No evidence
of disease activity (NEDA), also referred to
as freedom from disease activity, is a new
goal that is emerging in multiple sclerosis
treatment. Earlier treatment discontinuation
as observed here may be expected in future
cohorts. 
Treatment discontinuation in case of
neutralizing antibodies leads to treatment
change in Finland. The percentage of
patients with neutralizing antibodies in our
cohort was 15 %, while in the PRISMS
study the percentages were 23.8% in 22 µg
and 12.5% in 44 µg.16 Efficacy of interfer-
on- β-1a has been shown to decrease with
neutralizing antibody formation, highlight-
ing the importance of neutralizing antibod-
ies to clinical response.17,18 The improved
formulation of interferon β-1a s.c tiw,
which has been available since 2007, was
shown to reduce the number of patients
developing neutralizing antibodies, and its
introduction to clinical praxis is likely the
cause for the lower percentage seen also
here.19 Similar percentages have been
reported in more recent studies.20
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Figure 3. Longitudinal analysis showing OR’s with 95% confidence intervals by clinical
prognostic variables. Disability progression risk is increased if OR > 1.0 during the treat-
ment period.
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Interferon β-1a s.c tiw was discontinued
also in case of pregnancy or planned preg-
nancy. Due to large amount of data, which
was collected from registries and post-mar-
keting experience on pregnancies during
interferon β-1a treatment, a label change for
interferon β-1a treatments was recently
done. Currently, if clinically needed, the use
of interferon β-1a s.c tiw may be considered
during pregnancy, and interferon β-1a ther-
apy can be used during breast-feeding.21,22
Therefore, interferon β-1a tiw may be use-
ful among fertile young women wishing to
become pregnant.
Real-life experience and reports on over
15 years of long-term use of interferon β-1a
tiw has shown good safety profiles.2 Here
the side effects weakened the treatment
adherence and lead to discontinuation in
about a quarter of cases, which is lower than
the 35.7% reported in i.m interferon β-1a
community-based cohort (n=364).23 In our
study common side effects were injection
site side effects, flu like reactions and
increase in laboratory values, while no seri-
ous side effects were observed, which is in
line with previous reports.16,23 Experience
on patient education on these side effects
prior to treatment, and proper management
of adverse events improves adherence to
treatment and these actions to diminish
side-effects are needed to reach long-term
treatment tolerance with interferon β-1a s.c.
tiw.24,25
The prognostic factors recognized in
this study point at young age, a short time to
treatment initiation, and slower disability
progression during the follow up. There is a
need for regular clinical follow-up to con-
trol for disease activity and a need for con-
tinuous patient education to improve treat-
ment adherence. 
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